TRC150094, a Novel Mitochondrial Modulator, Reduces Cardio-Metabolic Risk as an Add-On Treatment: a Phase-2, 24-Week, Multi-Center, Randomized, Double-Blind, Clinical Trial

Overview of attention for article published in Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, February 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Above-average Attention Score compared to outputs of the same age and source (61st percentile)

Mentioned by

twitter: 2 X users

facebook: 1 Facebook page

Readers on

mendeley: 18 Mendeley

Summary X Facebook

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 3,539 followers.

TRC150094, a Novel Mitochondrial Modulator, Reduces Cardio-Metabolic Risk as an Add-On Treatment: a Phase-2, 24-Week, Multi-Center, Randomized, Double-Blind, Clinical Trial https://t.co/CyBej4kGar

25 Feb 2022

Reply Repost Favourite

TRC150094 Reduces Cardio-metabolic Risk as Add-on Treatment | DMSO - Dove Medical Press https://t.co/AqzO5um62O #diabetes #vingscommunity #news

24 Feb 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.